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A B S T R A C T
Blockade of the renin-angiotensin system (RAS) is now recognized as an effective 
means of lowering blood pressure and protecting hypertensive patients from end-
organ damage. There are three pharmacologic approaches to blockade of the RAS, 
with angiotensin-converting enzyme (ACE) inhibitors, with angiotensin II receptor 
blockers (ARBs), and with direct renin inhibitors. Clinical studies with the first two 
classes have shown that neither one achieves complete blockade of the RAS. However, 
an almost complete blockade of the RAS can be achieved by combination of an ACE 
inhibitor plus an ARB, albeit not with consistent benefits. A complete blockade of the 
RAS can also be obtained by combination of an ARB with a renin inhibitor. Further 
outcome trials are needed to show which combination offers long-term advantages in 
terms of end-organ protection.
Blockade of the renin-angiotensin system (RAS)1-8 is now recognized as an ef-
fective means of lowering blood pressure and protecting hypertensive patients from 
end-organ damage. There are nowadays three pharmacologic approaches to blockade 
of the RAS: with angiotensin-converting enzyme (ACE) inhibitors, introduced in the 
1970s, with angiotensin II (Ang II) AT1 receptor blockers (ARBs), introduced in the 
1990s, and with direct renin inhibitors, a new class whose first agent, aliskiren,8 was 
introduced in 2006. Clinical studies with the first two classes have shown that neither 
one achieves complete blockade of the RAS. With chronic use of ACE inhibitors, there 
is a gradual return of Ang II towards pretreatment levels because enzymes other than 
ACE, e.g., chymase and others, can cleave off two aminoacids from the decapeptide 
angiotensin I, even though there is no evidence of “escape” in terms of blood pressure 
control. With ARBs there is a partial blockade of AT1 receptors of variable degree and 
duration, depending on the affinity of each agent for the receptor and of the duration 
of the blockade (surmountable or insurmountable).
It has now been shown that an almost complete blockade of the RAS can be 
achieved by combination of an ACE inhibitor plus an ARB.9 There has been clinical 
evidence that a more complete blockade of the RAS may offer benefits in terms of 
end-organ protection even beyond those of optimal blood pressure control, e.g. by 
arresting or reversing the progression of diabetic or other nephropathies (COOP-
ERATE trial).10 One such trial, the ONTARGET study of telmisartan and ramipril 
combination, published recently,11 showed that combination of the two agents achieved 
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a small additional blood pressure lowering compared to mono-
therapy with either one. Not surprisingly, telmisartan tended 
to be better tolerated than ramipril. However, there was no 
advantage with the combination in terms of outcome; in fact, 
there was a trend to increased adverse reactions, especially 
renal impairment, which was puzzling. Nevertheless, these 
data are not much different from those reported in the past for 
treatment of acute myocardial infarct with valsartan and cap-
topril alone or in combination (the VALIANT study).12 This 
is in contrast to two heart failure studies of ACEI plus ARB 
combinations, the Val-HeFT and CHARM trials, in which 
the ARBs valsartan and candesartan, respectively, showed 
additional benefits when added to ACE inhibitor therapy.13,14
A complete blockade of the RAS can also be obtained 
by combination of an ARB with a renin inhibitor. One such 
study15 demonstrated that combination of the ARB valsartan 
with the renin inhibitor aliskiren, produced a significantly 
greater blood pressure decrease than either agent given as 
monotherapy. Such combination would be particularly desir-
able in cases, where total suppression of the RAS is desirable, 
but the patient is intolerant to ACE inhibition (because of 
cough or angioedema). Further outcome trials are needed to 
show whether ARB plus renin inhibitor combination offers 
additional long-term advantages in terms of end-organ protec-
tion when compared to different drug combinations achieving 
the same degree of blood pressure lowering.
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